The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

WATERVILLE— More than 17,000 Mainers are expected to be diagnosed with non-melanoma skin cancer this year, according to Maine ...

Such as polynucleotides, Profhilo to help maintain hydrated healthy skin. Chemical peels and lasers are another staple to ...

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...

It's been spectacularly successful, but with $17 billion-a-year Keytruda (pembrolizumab) now accounting for more than a third of its total sales there has been pressure on the company to diversify.

Similar percentages of patients with PsA receiving secukinumab vs adalimumab achieved an ACR20 response at 12 weeks.

Anybody who has oral, anal, or vaginal sex, or genital skin-to-skin contact with another person can ... Planned Parenthood health centers offer STD testing and treatment, and our caring and ...